Date: 2013-04-17
Type of information: Fundraising
Company: Rodos BioTarget (Germany)
Investors: InvestImpuls-Fonds of the region of Hannover
Amount: € 2.6 million
Funding type:
Planned used: Current growth investment funds will finance all measures required to enter into clinical trials which will establish the TargoSphere® for the targeted delivery of active agents and vaccines into antigen-presenting cells. RBT has already achieved a crucial milestone in development of an industrially up scaled and GMP-compliant production process of its proprietary platform nanotechnology, the TargoSphere®. RBT’s TargoSphere® nanocarriers effectively deliver potent active compounds and vaccines directly into antigen-presenting cells of the immune system, resulting in site-specific therapeutic or protective actions. Novel therapeutic interventions can now be developed against infectious diseases and cancers, as well as against autoimmune diseases. Based on the TargoSphere®, RBT is currently developing an antiviral therapy (TargoVir) against Hepatitis C and HIV/AIDS, as well as antibacterial therapies (TargoBiotics) for newly developed applications, including pulmonary infections.
Others: Rodos BioTarget has realized corporate investment financing in the amount of € 2.6 million, with additional option payments attached to its milestones for 2013. Institutional investors participating in this round included the InvestImpuls-Fonds of the region of Hannover (Germany) under the management of EnjoyVenture, the High-Tech Gründerfonds and the KfW’s ERP Start Fund. In addition to institutional investors, RBT was able to attract private domestic capital (family office and business angels).
Therapeutic area: Cancer - Oncology - Infectious diseases
